Assessing a new questionnaire for neuropsychiatric fluctuations in Parkinson's disease
Official title: Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale (EFN)
Run by University Hospital, Grenoble · NCT06701955 · Data updated 2026-11-12
This study is testing a new questionnaire to see if it can reliably measure mood and behavior changes in people with Parkinson's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Status | Recruiting |
| Started | January 30, 2025 |
| Main results expected | February 1, 2027 |
| Study ends | February 1, 2027 |
| Registry record updated | September 30, 2026 |
| Trial ID | NCT06701955 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 30 to 75 with idiopathic Parkinson's disease experiencing motor fluctuations.
✕Probably not a fit
Patients with Parkinsonian syndromes other than idiopathic Parkinson's disease or those with significant cognitive impairment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the Neuropsychological Fluctuations Scale (NFS), a 20-item questionnaire designed to assess neuropsychiatric fluctuations in patients with Parkinson's disease. The research aims to establish the test-retest reliability of the NFS, which has shown promising psychometric properties in previous studies. Participants will complete the questionnaire and undergo a physical exam to ensure comprehensive evaluation. This validation step is crucial for confirming the NFS as a reliable tool for assessing non-motor symptoms in Parkinson's disease.
Why it matters
Potential benefit: If successful, this study could provide a validated tool for better assessing and managing neuropsychiatric symptoms in Parkinson's disease, ultimately improving patient care.
How similar studies have gone: Previous studies have shown promising results with similar assessment tools, indicating potential for success in this validation effort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Age \> 30 and ≤ 75 years * Idiopathic Parkinson's disease (according to the criteria of the Movement Disorders Society) * Presence of motor fluctuations described by the patient, their relatives, or identified by the clinician * Stability of antiparkinsonian treatment for at least one month * Mastery of the French language * Able to give consent. * Affiliated to the social security system Exclusion Criteria: Parkinsonian syndrome other than idiopathic Parkinson's disease * Dementia (MoCa \< 23) * No antiparkinsonian treatment or treatment modified for less than one month * Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, parturients, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social establishment for purposes other than research, minors, persons subject to a legal protection measure or unable to express their consent)) * Subject in a period of exclusion from another interventional study.
Where it's running
-
Chuga
Grenoble, France Recruiting
Study contacts
- Study coordinator: Emmanuelle Schmitt, PHD
- Email: eschmitt@chu-grenoble.fr
- Phone: +33 4 76765791
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using deep rTMS to improve memory in Alzheimer's Disease
This study is testing if a new brain treatment called deep rTMS can help improve memory in people with mild to moderate Alzheimer's Disease.
-
Scalp EEG mapping of DBS-induced electric fields
This will test whether very high–sampling-rate EEG can record the electric fields produced by DBS in people with Parkinson's disease or related movement disorders who already have implants.
-
GM101 injection to reprogram putamen cells for Parkinson's disease
This trial will test an experimental gene therapy called GM101, given by brain injection, to see if it is safe for people aged 40–70 with Parkinson's disease lasting five years or more.
-
Targeted mechanical stimulation used at home to relieve tremors
This project will try a wearable device that delivers targeted mechanical stimulation at home to reduce moderate-to-severe upper limb tremors in adults with essential tremor or Parkinson's disease.
-
Using brain stimulation to improve memory and motivation in older adults
This study is testing if a type of brain stimulation can help improve memory and motivation in older adults, including those showing early signs of Alzheimer's disease.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.